Title

Obesity-related brain atrophy occurs through mechanisms independent of Alzheimer's disease pathology

Authors

Filip Morys[1,2], Lang Liu[1,2,3], Konstantin Senkevich[1,2,3,4], Ziv Gan-Or[1,2,3], Alain Dagher[1,2]

[1]   The Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal, QC, Canada

[2]   Department of Neurology and neurosurgery, McGill University, Montréal, QC, Canada

[3]   Department of Human Genetics, McGill University, Montréal, QC, Canada

[4]   Department of Specialized Medicine, Division of Medical Genetics, McGill University Health Centre, Montreal, QC, Canada.

Corresponding author

Filip Morys

filip.morys@mcgill.ca

Abstract

Obesity increases the risk for Alzheimer's disease (AD) and related dementias, likely through structural brain changes in the same regions as AD. The mechanisms underpinning brain atrophy in AD involve the deposition of misfolded and dysfunctional tau and β-amyloid proteins, but are not well understood in obesity. Here, we tested whether obesity, cerebrovascular disease, and obesity-related metabolic risk score were associated with structural brain and cognitive changes via the same mechanisms as AD or independent of them. We used the microtubule-associated protein tau (*MAPT)* and apolipoprotein E (*APOE)* genotypes involved in tau and β-amyloid synthesis, folding, and clearance, as well as AD polygenic risk score (PRS) to define vulnerability to protein deposition. We then tested whether those factors moderated the relationship between obesity, brain structure, and cognition. A significant moderation would imply that obesity may affect brain structure via mechanisms involving tau and β-amyloid deposition. We found that *MAPT* and *APOE* status as well as AD PRS did not moderate the relationship between obesity and brain structure. We also found sparse evidence for the moderation of *MAPT* and *APOE* of the cerebrovascular disease-brain structure relationship as well as the metabolic risk score-brain structure relationship. We conclude that the mechanisms linking obesity with brain atrophy are most likely independent of the ones governing AD-related brain atrophy and might involve cerebrovascular factors.

Keywords

1. Introduction

Among the most significant risk factors for Alzheimer's Disease (AD) are age, family history, and obesity and its associated metabolic dysfunctions (Silva et al., 2019; Yu et al., 2020). However, how genetic risk and obesity interact to cause neurodegeneration with advancing age is not known.

AD is caused by the progressive accumulation and propagation of abnormal isoforms of β-amyloid and tau, which aggregate as plaques and neurofibrillary tangles (Busche & Hyman, 2020). These proteins are neurotoxic and their accumulation is associated with loss of neurons, synapses, and neuropil, which can be detected as cortical volume loss and white matter damage with magnetic resonance imaging (MRI) (Bayram et al., 2018). Longitudinal MRI studies in AD have demonstrated a spatially stereotyped and progressive pattern of cortical thinning (Planche et al., 2022).

The expression, function, and deposition of tau and β-amyloid are regulated by the genes encoding microtubule-associated protein tau (*MAPT*) and apolipoprotein E (*APOE*). The *MAPT* gene regulates the expression and function of tau protein and in European populations is represented by H1 and H2 haplotypes (Spillantini & Goedert, 2013). The H1 haplotype is an ancestral inversion at chromosome 17q21 that includes several genes besides *MAPT* (Zody et al., 2008). H1 is a risk factor for a number of neurodegenerative diseases, including Parkinson's disease, progressive supranuclear palsy, frontotemporal dementia and corticobasal degeneration (Sánchez-Juan et al., 2019). The H1 haplotype has also been associated with AD, and with a higher risk of dementia in PD (Pastor et al., 2016; Sánchez-Juan et al., 2019; Setó-Salvia et al., 2011).

The *APOE* gene has three alleles - ε2, ε3, and ε4 - and its product apolipoprotein E is associated with cholesterol transport and regulation of β-amyloid seeding, aggregation, and deposition (Kanekiyo et al., 2014). The ε4 allele confers an increased risk of AD (Martens et al., 2022; Sun et al., 2023). Additionally, the risk of AD is linked to other genes involved in neuroinflammation, endocytosis, or lipid metabolism (Bellenguez et al., 2022). These genes can be incorporated into a polygenic risk score (PRS), which is associated with earlier age of onset and higher annual incidence of AD.

Obesity in middle-age is associated with cerebrovascular dysfunction, grey and white matter atrophy, and cognitive decline (García-García et al., 2022; Morys et al., 2021). Animal and human studies show that adiposity-related factors leading to brain injury are hypertension, diabetes and insulin resistance,, inflammation, and dyslipidemia, labelled together as metabolic syndrome (García-García et al., 2022; Lloret et al., 2019; Moroz et al., 2008; Morys et al., 2021; Pedditizi et al., 2016; Walker et al., 2017). In addition, the cortical atrophy pattern associated with higher BMI in middle-age overlaps spatially with that described in AD

(Morys et al., 2023). This suggests that chronic obesity may lead to brain injury that predisposes people to AD.

However, whether adiposity-related brain atrophy is associated with true AD pathology remains unknown, although some evidence points towards an association. For instance, insulin resistance can directly cause cerebrovascular dysfunction, but it also contributes to the accumulation of β-amyloid and related neurotoxicity (de la Monte, 2012; Mullins et al., 2017). Similar dual effects on cerebral vasculature and protein accumulation are observed in relation to hypertension, inflammation, and dyslipidemia (García-García et al., 2022; Iadecola & Gottesman, 2019; Kinney et al., 2018; Mun & Hinman, 2022; Reitz, 2013; van den Kerkhof et al., 2023). Indeed, obesity-induced neural damage and AD may share underlying mechanisms, including the deposition of dysfunctional tau and β-amyloid isoforms (Meakin et al., 2020; Platt et al., 2016; So et al., 2023).

Nonetheless, the mechanistic pathways leading from obesity to AD are largely unexplored. One possibility is that prolonged adiposity damages the brain, setting the stage for the amyloid/tau cascade of AD in vulnerable individuals (Edwards, 2019). This theory suggests that metabolic syndrome-induced cerebrovascular and neuronal injury triggers the accumulation of abnormal amyloid and tau proteins, particularly in genetically predisposed individuals (e.g., those carrying high-risk variants such as *APOE4*, *MAPT* H1, or a high PRS for AD). If this is the case, then genetic risk for AD should moderate the relationship between metabolic syndrome and brain atrophy (Mole et al., 2020). Conversely, metabolic injury and genetics may act independently (Cogswell et al., 2023; Morys et al., 2023; Pegueroles et al., 2020). For example, adiposity-related brain damage may lower the threshold to dementia by reducing cognitive reserve independently of amyloid or tau deposition. In this case, obesity and genetic risk would have independent effects on brain atrophy.

There are now emerging treatments for both obesity and AD-related proteinopathy, making it important to better understand the interaction of these two processes. Here, we examine the role of genetic risk in modulating the relationship between obesity and brain atrophy and cognitive function. Specifically, we look for interactions between obesity measures and *MAPT* and *APOE* genotypes and AD PRS. We use the UK Biobank (UKBB) dataset with its extensive phenotypic and genetic information to test the two mentioned mechanisms in a large sample of over 30,000 individuals. Overall, our findings mostly support an independent role for genetic risk and adiposity.

2. Materials and methods

a. Participants

The UKBB sample is a large-scale, multi-site study conducted in the UK (Miller et al., 2016; Sudlow et al., 2015). The current research was performed under UKBB study ID 45551. Prior to all analyses we excluded individuals with neurological disorders diagnosed before the neuroimaging timepoint and we only included individuals who participated in the neuroimaging session. Participants gave written informed consent and the study was approved by the North-West Multi-Centre Research Ethics Committee. All ethical regulations relevant to human research participants were followed. The sample size for this study was 33,769 (mean age=64 years, SD=9; mean BMI=26.21kg/m^2, SD=3.97; 17,210 women).

b. Neuroimaging data

Neuroimaging data were collected using 3T Siemens Skyra scanners at 3 sites in the UK. Imaging protocol details are described online at https://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=2367 and in previous publications (Miller et al., 2016). We used T1-weighted structural images with a 0.8mm3 isotropic voxel size. Here, we used cortical thickness and cortical surface area imaging-derived phenotypes for each parcel of the Desikan-Killiany-Tourville atlas provided by the UKBB (Alfaro-Almagro et al., 2018; Klein & Tourville, 2012; Littlejohns et al., 2020) as well as subcortical volume measurements for the following regions of interest: thalamus, caudate, putamen, pallidum, hippocampus, amygdala, and nucleus accumbens. To investigate white matter microstructure, we used mean diffusivity and fractional anisotropy values for 48 standard parcels from the Johns Hopkins University white matter atlas provided by UKBB (Mori et al., 2005; Wakana et al., 2007). Finally, we used total volume of white matter hyperintensities (WMH) as a better proxy of cerebrovascular disease than BMI. Cortical data were obtained using FreeSurfer 6.0.0, subcortical volumes were derived using Functional Magnetic Resonance Imaging of the Brain (FMRIB)'s Integrated Registration and Segmentation Tool (FIRST), FA and MD were obtained using custom-made scripts, while WMH was obtained using Brain Intensity AbNormality Classification Algorithm (BIANCA) (Fischl, 2012; Griffanti et al., 2016; Jenkinson et al., 2012; Patenaude et al., 2011). Automated quality control was performed by the UKBB initiative.

c. Genotyping data quality control and haplotype analysis

We analysed 487,410 samples from the 2019 release of the UK Biobank (UKB), applying standard genotyping quality control measures as described by Bycroft et al. (Bycroft et al., 2018). We excluded individuals of non-European ancestry, determined through both

self-reported data and genetic principal component analysis. Further exclusions were made for individuals with relatedness closer than that of first cousins. Data from participants whose self-reported sex did not correspond to their genetic sex were removed from the dataset. In addition, SNPs with minor allele frequency (MAF) < 1%, missing rate > 1%, imputation quality INFO score < 0.3, and significant deviation from Hardy-Weinberg equilibrium (HWE) with $P < 1 \times 10^{-10}$ were excluded. MAPT haplotypes were based on genotypes of rs1052553 (H1: A; H2: G). *APOE* alleles were based on combinations of genotypes derived from rs429358 and rs7412 (ε2: rs429358 T/ rs7412 T; ε3: T/C; ε4: C/C). There were 8,666 *APOE ε4* carriers (heterozygous and homozygous) and 20,337 *MAPT* H1 carriers (heterozygous and homozygous).

d. Alzheimer's disease polygenic risk score calculation

The AD PRS was calculated using the posterior effect size of SNPs inferred from the latest GWAS summary statistics (Bellenguez et al., 2022). The posterior effect size was calculated by PRS-CS, a software that applies a Bayesian regression framework, continuous shrinkage (CS) priors and the linkage disequilibrium reference panel from 1000 Genome Projects European samples on SNP effect sizes (Ge et al., 2019).

e. Obesity-related variables

BMI was used as a main indicator of obesity. In addition, we investigated the following measures of obesity-related metabolic dysfunction: serum C-reactive protein, non-fasting plasma glucose, plasma glycated haemoglobin A1c (HbA1c), systolic and diastolic blood pressure, plasma triglycerides, total cholesterol, high density lipoprotein and low density lipoprotein, as well as waist-to-hip ratio and body fat percentage. Blood sampling and handling are described in (Elliott et al., 2008). All blood parameters were collected at a baseline timepoint, which took place on average 8 years prior to the brain imaging timepoint. Weight and body fat percentage were measured with the Tanita BC418ma bioimpedance device (Tanita, Tokyo, Japan) during the imaging visit. Metabolic variables were selected based on our previous work (Morys et al., 2021).

f. Cognitive measures

To test the influence of AD genetic risk and obesity on cognition, we used the following cognitive measures provided by the UK Biobank (Cullen et al., 2015; Fawns-Ritchie & Deary, 2019): 1) working memory (digit span task); 2) fluid intelligence (set of reasoning tasks); 3) executive function (tower rearranging test); 4) prospective memory (number of times an intention was forgotten on a prospective memory task); 5) visuospatial memory (pairs matching task); 6) reaction time (button press task). Because tests of visuospatial memory

and reaction time were administered more than once, we used an average value of all trials. For prospective memory, visuospatial memory, and reaction time, higher scores indicate worse performance. Cognitive measures were collected during the imaging visit.

g. Statistical analyses

Statistical analysis was performed in R (v. 4.3.1). We began by investigating the associations between genotypes of interest (*APOE ε4*, *MAPT* H1, AD PRS) and brain and cognitive measures of interest - cortical thickness, cortical surface area, subcortical volumes, white matter FA and MD, and cognition. We used general linear model analysis with genetic measures as predictors and brain or cognitive measures as outcome variables. Next, to investigate the relationship between obesity and neurocognitive phenotypes, we used the GLM analysis with BMI as a predictor variable and brain/cognitive measures as outcome variables. To investigate whether the relationship between BMI, brain structure and cognition differed as a function of *MAPT*/*APOE* genotype or AD PRS, we introduced an interaction term between BMI and genotype/PRS in the GLM. Next, we performed similar GLM analyses with WMH volume as a predictor variable instead of BMI. This was only done for grey matter measures and cognition as outcome variables due to high collinearity between WMH and white matter FA and MD. Finally, to capture the combined effect of multiple obesity-related variables, we first ran a principal component analysis with *varimax* rotation to identify a latent variable that encompasses all obesity-related variables in this study. We used scores of the first rotated component (explaining 24% of total variance in all obesity-related variables; Table S1, Figure S1) representing overall cardiometabolic risk as a predictor variable in GLMs analogous to the previous analyses with BMI and WMH volume. According to the best available practices, GLM analyses included the following covariates: age, sex, age^2, age*sex, age^2*sex, imaging site, time difference between imaging acquisition of the first participant and each remaining participant, time difference squared (not for cognitive analysis), as well as genotype measurement batch and first 15 genetic principal components (Alfaro-Almagro et al., 2021). These covariates were included to control for potential confounding effects of demographics, imaging protocols, and genetic ancestry. We corrected for multiple comparisons using false discovery rate separately for each analysis modality (e.g. cognition or cortical thickness) (Benjamini & Hochberg, 1995). Scripts used to analyse the data for this study are available at https://github.com/FilipMorys/MAPT_ApoE.

3. Results

   a. *APOE* ε4 status, *MAPT* H1 haplotype and AD PRS associations with neurocognitive phenotypes

We found significant widespread differences in multiple brain and cognitive measures between *APOE* ε4 carriers and non-carriers, as well as individuals with H1 vs. H2 haplotypes. *APOE ε4* carriers showed higher cortical surface area in frontal and occipital brain areas and lower cortical thickness predominantly in the temporal and frontal brain areas, as well as lower volumes of the bilateral thalamus and hippocampus (Figure 1a-b, Tables S2-S3). They also showed lower FA in posterior brain regions and higher MD in anterior brain regions (Figure 2a-b, Table S4). *APOE ε4* carriers also had poorer visuospatial memory, prospective memory, fluid intelligence, working memory, and executive function (Table S5).

Individuals with *MAPT* H1 haplotype showed higher surface area globally as well as lower cortical thickness in the frontal, temporal, and occipital lobes (Figure 1c, Table S6). H1 haplotype was also associated with lower volumes of the bilateral putamen and nucleus accumbens (Figure 1d, Table S7), as well as higher FA and lower MD throughout the white matter (Table S8, Figure 2c-d). Individuals with *MAPT* H1 haplotype had better working memory (Table S9). Finally, AD PRS was not significantly associated with any brain phenotypes (Tables S10-S12), but was associated with worse prospective memory, fluid intelligence, and executive function (Table S13).

Figure 1 Associations between genotypes and grey matter phenotypes; **a/b** - *APOE* ε4 carriers vs. non-carriers; **c/d** - MAPT H1 vs H2 haplotype.

Figure 2 Associations between genotypes and grey matter phenotypes; **a** - fractional anisotropy in *APOE* ε4 carriers vs. non-carriers; **b** - mean diffusivity in *APOE* ε4 carriers vs. non-carriers; **c** - fractional anisotropy in *MAPT* H1 vs H2 haplotype; **d** - mean diffusivity in *MAPT* H1 vs H2 haplotype.

b. Associations between BMI, genotype, and grey matter

We found significant negative relationships between BMI and cortical thickness in the
bilateral fronto-temporal and cingulate brain regions, as well as positive relationships in the
occipital, parietal, and dorsal frontal regions (Figure 3a, Table S14). In terms of cortical
surface area, BMI showed mainly negative associations in the temporal, occipital, parietal,
and frontal brain regions (Figure 3a, Table S14). Subcortical volumes were negatively
associated with BMI with the exception of the left amygdala, which showed a positive
association with BMI and right amygdala, which showed no association (Figure 3b, Table
S15). *MAPT* genotype, *APOE* genotype, and AD PRS did not moderate the relationship
between BMI and grey matter phenotypes (Figure 3c-1f, Tables S16-S21), suggesting that
the effects of BMI and AD genetic risk on the brain are independent.

Figure 3 Associations between body mass index (BMI) and grey matter phenotypes; **a** Relationship between BMI
and cortical thickness (CT) and surface area (SA); **b** relationship between BMI and subcortical volumes; **c-f**
effects of genotypes on cortical thickness and surface area in regions significantly related to BMI.

c. Associations between WMH volume, genotype, and grey matter

WMH volume was associated with widespread greater surface area and reduced cortical
thickness (Figure S2a, Table S22). WMH volume was also significantly negatively associated
with subcortical volumes except the caudate nucleus, which showed a positive association

(Figure S2b, Table S23) (Dadar et al., 2021). We found that *APOE* genotype moderated the relationship between WMH volume and bilateral hippocampal volume. Here, the negative slope of the relationship between WMH volume and hippocampal volume was steeper for *APOE* ε4 carriers (Figure S2c). We also found a moderating effect of *MAPT* genotype on the relationship between WMH volume and pallidum volume. The relationship between WMH load and pallidum volume was positive for individuals with H1 haplotype, and negative for individuals with H2 haplotype (Figure S2d). No other significant moderating effects were found (Tables S24-S29).

d. Associations between metabolic risk score, genotype, and grey matter

The first rotated component from PCA analysis representing an obesity metabolic risk score was negatively associated with cortical surface area in most brain regions, negatively related to cortical thickness in fronto-temporal and cingulate brain regions, and positively related to cortical thickness in occipital, parietal, and dorsal frontal regions (Figure S3a, Table S30). Metabolic risk score was also associated with lower volume of the bilateral thalamus, left putamen, bilateral pallidum, and bilateral nucleus accumbens, as well as higher volume of the left amygdala (Figure S3b, Table S31). We found significant moderating effects of the *APOE* genotype on the relationship between this component and cortical surface area, in which the slope of the relationship between surface area and metabolic risk score was positive for *APOE* ε4 carriers and negative for *APOE* ε4 non-carriers (Figure S3c-d). No other effects were found (Tables S32-S37).

e. Associations between BMI, genotype, and white matter

BMI showed widespread negative associations with FA in most brain regions - e.g., fornix, corona radiata, corpus callosum or cerebellar peduncles - with only a few positive associations with FA within the corticospinal tracts, pontine crossing tract, middle cerebellar peduncle, right posterior limb of internal capsule, and right cingulum hippocampus (Figure 4a, Table S38). BMI showed positive associations with MD, most notably within the superior fronto-occipital fasciculi, and anterior corona radiata, as well as negative associations within the middle cerebellar peduncle, pontine crossing tract, and corticospinal tracts (Figure 4b, Table S38). Overall, BMI-associated FA and MD changes overlapped, but showed opposite directions of associations. We found no moderating effects of genotype on the relationship between BMI and white matter microstructure measures (Figure 4c-4d; Tables S39-S41).

Figure 4 Associations between body mass index (BMI) and white matter microstructure; **a** Relationship between BMI and fractional anisotropy (FA); **b** relationship between BMI and mean diffusivity (MD); **c-f** effects of genotypes on fractional anisotropy and mean diffusivity in regions significantly related to BMI.

f. Associations between metabolic risk score, genotype, and white matter

Associations between metabolic risk score and white matter diffusivity measures mimicked the ones between BMI and white matter. Overall, more widespread negative associations were observed between the metabolic risk score and FA, with more widespread positive associations with MD (Figure S4, Table S42). No moderating effects of genotype were observed (Tables S43-45).

g. Associations between BMI, genotype, and cognition

Higher BMI was associated with longer reaction time, poorer prospective memory, lower fluid intelligence, and lower working memory (Table S46). We did not observe any moderating effects of genotype on the associations between BMI and cognitive functions (Tables S47-S49).

h. Associations between WMH, genotype, and cognition

Individuals with higher WMH volume had a longer reaction time, poorer prospective memory, lower fluid intelligence, poorer working memory, as well as lower executive functions (Table S50). The relationship between WMH and prospective memory was moderated by *APOE* genotype. Here, E4 carriers show a steeper negative relationship between WMH load and

prospective memory (Figure S5). No other significant associations were observed (Tables S51-S53).

        i.   Associations between metabolic risk score, genotype, and cognition

Overall metabolic risk score was associated with lower fluid intelligence and working memory (Table S54). In individuals with H1 haplotype we did not observe a significant relationship between the first principal component and visuospatial memory, while in individuals with H2 haplotype this relationship was negative (Figure S6). Remaining associations were not statistically significant (Tables S55-S57).

4. Discussion

Obesity is related to brain atrophy and increases the risk for AD (Morys et al., 2021; Nianogo et al., 2022). To investigate whether the mechanisms governing AD and obesity-related brain changes act in synergy, we tested whether genetic risk for AD moderates the relationship between obesity and brain atrophy. We utilised BMI as a measure of obesity, but also created a comprehensive metabolic risk score. We also used WMH volume as a direct measure of cerebrovascular disease. We first investigated how genes involved in tau and β-amyloid expression and clearance (*MAPT* and *APOE*) as well as AD PRS affect brain structure and cognition. We then examined whether these genetic factors moderate the effect of BMI, metabolic risk score, and WMH volume on brain and cognition. We showed strong effects of *MAPT* and *APOE* genes as well as WMH, obesity and associated variables on all investigated neurocognitive phenotypes. However, there was limited evidence for an influence of AD-related genetic risk on obesity-brain structure/cognition associations. This argues that obesity itself, as measured by BMI, might cause brain injury independent of AD pathology.

On the other hand, we did find some evidence of AD genetic risk moderation on the associations of WMH and metabolic risk scores with brain structure. Specifically, we found that *APOE* ε4 gene carriers displayed a more negative relationship between WMH volume and hippocampal volume. We also found that *APOE* ε4 status moderated the relationship between overall metabolic risk score and cortical surface area, as well as WMH volume and prospective memory. Finally, *MAPT* haplotype only moderated the relationship between overall metabolic risk score and visuospatial memory.

Effects of *APOE* ε4, *MAPT* H1, and AD PRS on brain structure and cognition

In line with previous studies, we found that *MAPT* H1 haplotype and *APOE* ε4 genotype were strongly associated with all investigated domains of brain structure and cognition. Most notably, *APOE* ε4 was associated with lower cortical thickness and hippocampal and

thalamic volume, which are hallmarks of AD (O'Dwyer et al., 2012; Pievani et al., 2011). At the same time, *MAPT* H1 haplotype was associated with higher surface area globally, as well as decreased cortical thickness. The positive association with cortical surface area are in line with recent literature on *MAPT* inversion and underscore the role that *MAPT* plays in brain development conferring an evolutionary advantage, given that cortical surface area is determined genetically at an early age, and *MAPT* expression seems to be greatest during the prenatal period (Grasby et al., 2020; Wang et al., 2023). *MAPT* H1 was also associated with denser white matter microstructure and better working memory in our healthy sample. Overall, these effects of *MAPT* H1 could represent a neurodevelopmental influence that may account for one of the mechanisms by which it has been selected in the course of evolution. Finally, AD PRS was associated with slight reductions in cognitive function but not any of the investigated brain measures, suggesting that neuroanatomical effects might be too small to be found in this population.

Effects of obesity, metabolism, and cerebrovascular disease on brain structure and cognition

Obesity was associated with evidence of widespread cortical, subcortical and white matter injury. We found a typical fronto-temporal cortical thinning signature of obesity and metabolic risk score. This is in line with previous studies in this and other samples showing that obesity causes brain atrophy in areas similar to the ones affected in AD (García-García et al., 2019; Hamer & Batty, 2019; Morys et al., 2021, 2023). Lower subcortical volumes with BMI are also in line with previous reports (Morys et al., 2021). Our findings of altered white matter microstructure are also consistent with the literature (Daoust et al., 2021; Karlsson et al., 2013; Zhang et al., 2018). The widespread lower cortical surface area with obesity is somewhat novel. We also show that WMH volume, a measure of chronic ischemic damage, is associated with lower cortical thickness and volume of subcortical structures, supporting the fact that cerebrovascular dysfunction in obesity leads to grey matter injury (Dadar et al., 2018).

Relative absence of moderating effects of AD-related genes

Our investigation of moderating effects of AD-related genes on BMI-related brain atrophy revealed that obesity mostly affects brain structure independent of AD pathophysiology. In other words, genes affecting the deposition of tau and β-amyloid, as well as AD PRS, did not alter how obesity is associated with all tested grey and white matter phenotypes, as well as cognition. Overall, our findings support the hypothesis that obesity-related brain atrophy and cognitive decline are likely cerebrovascular/metabolic in nature and do not depend on the deposition of dysfunctional proteins associated with AD.

Nonetheless, we did find some limited moderating effects of *APOE* and *MAPT* genotypes on some obesity-brain relationships. For example, *APOE* ε4 carriers have a more negative relationship between WMH volume and hippocampal volume. This is in line with literature showing lower hippocampal volumes in *APOE* ε4 carriers and suggests that cerebrovascular disease might potentiate this relationship (O'Dwyer et al., 2012; Pievani et al., 2011). Interestingly and opposed to the relationship with BMI, we found that *APOE* ε4 status moderates the relationship between metabolic risk score and cortical surface area. Conceivably, metabolic derangements associated with obesity affect the brain differently than BMI and this relationship seems to be dependent on the *APOE* genotype. The *APOE* gene controls not only the processing and clearance of β-amyloid, but also cholesterol transport or neuroinflammation, amongst others (Mahley, 1988; Martens et al., 2022). *APOE* ε4 can also lead to vascular dysfunction and neuroinflammation through non-amyloid dependent pathways (Martens et al., 2022). As such, this could mean that the moderation of *APOE* on the metabolic risk score-brain structure relationship is due to the functions of apolipoprotein E unrelated to β-amyloid deposition, especially given that the metabolic risk score captures factors such as hypercholesterolemia and systemic inflammation.

Conclusions

Given that most analyses performed in this study showed that there are no moderating effects on the relationship between BMI, metabolism, or WMH volume and the brain, we conclude that it is likely that the effects of obesity on the brain are mostly cerebrovascular in nature rather than directly involving tau and amyloid accumulation. How can obesity lead to AD in this scenario? It is possible that some brain regions (such as the medial temporal lobe) are inherently more vulnerable to damage. These brain regions are affected by obesity, and in individuals with a high risk for AD, this could be enough to facilitate or potentiate the AD-related pathology and lead to the disease. Indeed, the one mediating effect of genetics here was one of *APOE* ε4 genotype on the relationship between cerebrovascular damage and hippocampal atrophy.

The findings of this study should be considered within the context of its limitations. The cross-sectional nature of the dataset prevents us from making definitive conclusions about causality and directionality of associations. Further, the genes investigated here are not direct measures of protein deposition. As such, some of our results are not necessarily indicative of the associations of obesity-related variables with β-amyloid deposition. Overall, this study supports the hypothesis that obesity does not cause neurodegeneration through the deposition of dysfunctional AD proteins. This opens avenues to investigate alternative pathways, potentially leading to new therapeutic targets. Clinically, the findings highlight the need for interventions that focus on weight management and correcting metabolic

abnormalities, rather than solely targeting protein deposition, to better preserve brain health in obese individuals at risk for AD and other dementias.

5. Data and code availability

Data used in this study are available upon request from the UK Biobank. Code used to analyse the dataset is deposited at https://github.com/FilipMorys/MAPT_ApoE.

6. Author contributions

FM, ZGO, and AD conceptualised the study, FM, LL, KS analysed the data, AD and ZGO supervised the work, FM and AD drafted the manuscript, all authors edited the final version of the manuscript.

7. Declaration of competing interests

Z.G.O received consultancy fees from Lysosomal Therapeutics Inc. (LTI), Idorsia, Prevail Therapeutics, Ono Therapeutics, Denali, Handl Therapeutics, Neuron23, Bial Biotech, Bial, UCB, Capsida, Vanqua bio, Congruence Therapeutics, Takeda, Jazz Guidepoint, Lighthouse and Deerfield. Remaining authors declare no competing interest.

8. Acknowledgements

AD was funded by the Canadian Institutes of Health Research. This research used the NeuroHub infrastructure and was undertaken thanks in part to funding from the Canada First Research Excellence Fund, awarded through the Healthy Brains, Healthy Lives initiative at McGill University. This research was enabled in part by support provided by Calcul Québec and the Digital Research Alliance of Canada. This research has been conducted using the UK Biobank Resource under Application Number 45551. Z.G.O. is supported by the Fonds de recherche du Québec—Santé (FRQS) Chercheurs-boursiers award and is a William Dawson Scholar.

9. References

Alfaro-Almagro, F., Jenkinson, M., Bangerter, N. K., Andersson, J. L. R., Griffanti, L., Douaud, G., Sotiropoulos, S. N., Jbabdi, S., Hernandez-Fernandez, M., Vallee, E., Vidaurre, D., Webster, M., McCarthy, P., Rorden, C., Daducci, A., Alexander, D. C., Zhang, H., Dragonu, I., Matthews, P. M., … Smith, S. M. (2018). Image processing and Quality Control for the first 10,000 brain imaging datasets from UK Biobank. *NeuroImage*, *166*, 400–424.

Alfaro-Almagro, F., McCarthy, P., Afyouni, S., Andersson, J. L. R., Bastiani, M., Miller, K. L., Nichols, T. E., & Smith, S. M. (2021). Confound modelling in UK Biobank brain imaging. *NeuroImage*, *224*, 117002.

Bayram, E., Caldwell, J. Z. K., & Banks, S. J. (2018). Current understanding of magnetic resonance imaging biomarkers and memory in Alzheimer's disease. *Alzheimer's & Dementia (New York, N. Y.)*, *4*, 395–413.

Bellenguez, C., Küçükali, F., Jansen, I. E., Kleineidam, L., Moreno-Grau, S., Amin, N., Naj, A. C., Campos-Martin, R., Grenier-Boley, B., Andrade, V., Holmans, P. A., Boland, A., Damotte, V., van der Lee, S. J., Costa, M. R., Kuulasmaa, T., Yang, Q., de Rojas, I., Bis, J. C., … Lambert, J.-C. (2022). New insights into the genetic etiology of Alzheimer's disease and related dementias. *Nature Genetics*, *54*(4), 412–436.

Benjamini, Y., & Hochberg, Y. (1995). *Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. 57*(1), 289–300.

Busche, M. A., & Hyman, B. T. (2020). Synergy between amyloid-β and tau in Alzheimer's disease. *Nature Neuroscience*, *23*(10), 1183–1193.

Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L. T., Sharp, K., Motyer, A., Vukcevic, D., Delaneau, O., O'Connell, J., Cortes, A., Welsh, S., Young, A., Effingham, M., McVean, G., Leslie, S., Allen, N., Donnelly, P., & Marchini, J. (2018). The UK Biobank resource with deep phenotyping and genomic data. *Nature*, *562*(7726), 203–209.

Cogswell, P. M., Lundt, E. S., Therneau, T. M., Mester, C. T., Wiste, H. J., Graff-Radford, J.,

Schwarz, C. G., Senjem, M. L., Gunter, J. L., Reid, R. I., Przybelski, S. A., Knopman, D. S., Vemuri, P., Petersen, R. C., & Jack, C. R., Jr. (2023). Evidence against a temporal association between cerebrovascular disease and Alzheimer's disease imaging biomarkers. *Nature Communications*, *14*(1), 3097.

Cullen, B., Nicholl, B. I., Mackay, D. F., Martin, D., Ul-Haq, Z., McIntosh, A., Gallacher, J., Deary, I. J., Pell, J. P., Evans, J. J., Smith, D. J., B., C., B.i., N., D.f., M., D., M., Z., U.-H., A., M., J., G., I.j., D., … Smith, D. J. (2015). Cognitive function and lifetime features of depression and bipolar disorder in a large population sample: Cross-sectional study of 143,828 UK Biobank participants. *European Psychiatry: The Journal of the Association of European Psychiatrists*, *30*(8), 950–958.

Dadar, M., Potvin, O., Camicioli, R., Duchesne, S., & Alzheimer's Disease Neuroimaging Initiative. (2021). Beware of white matter hyperintensities causing systematic errors in FreeSurfer gray matter segmentations! *Human Brain Mapping*, *42*(9), 2734–2745.

Dadar, M., Zeighami, Y., Yau, Y., Fereshtehnejad, S. M., Maranzano, J., Postuma, R. B., Dagher, A., & Collins, D. L. (2018). White matter hyperintensities are linked to future cognitive decline in de novo Parkinson's disease patients. *NeuroImage: Clinical*, *20*, 892–900.

Daoust, J., Schaffer, J., Zeighami, Y., Dagher, A., García-García, I., & Michaud, A. (2021). White matter integrity differences in obesity: A meta-analysis of diffusion tensor imaging studies. *Neuroscience and Biobehavioral Reviews*, *129*, 133–141.

de la Monte, S. M. (2012). Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. *Drugs*, *72*(1), 49–66.

Edwards, F. A. (2019). A Unifying Hypothesis for Alzheimer's Disease: From Plaques to Neurodegeneration. *Trends in Neurosciences*, *42*(5), 310–322.

Elliott, P., Peakman, T. C., & UK Biobank. (2008). The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. *International Journal of Epidemiology*, *37*(2), 234–244.

Fawns-Ritchie, C., & Deary, I. J. (2019). Reliability and validity of the UK Biobank cognitive

tests. *medRxiv*, 19002204.

Fischl, B. (2012). FreeSurfer. *NeuroImage*, *62*(2), 774–781.

García-García, I., Michaud, A., Dadar, M., Zeighami, Y., Neseliler, S., Collins, D. L., Evans,
A. C., & Dagher, A. (2019). Neuroanatomical differences in obesity: meta-analytic
findings and their validation in an independent dataset. *International Journal of Obesity* ,
43(5), 943–951.

García-García, I., Michaud, A., María, ·., Jurado, Á., Dagher, A., & Morys, F. (2022).
Mechanisms linking obesity and its metabolic comorbidities with cerebral grey and white
matter changes. *Reviews in Endocrine & Metabolic Disorders*, *1*, 1–11.

Ge, T., Chen, C.-Y., Ni, Y., Feng, Y.-C. A., & Smoller, J. W. (2019). Polygenic prediction via
Bayesian regression and continuous shrinkage priors. *Nature Communications*, *10*(1),
1776.

Grasby, K. L., Jahanshad, N., Painter, J. N., Colodro-Conde, L., Bralten, J., Hibar, D. P.,
Lind, P. A., Pizzagalli, F., Ching, C. R. K., McMahon, M. A. B., Shatokhina, N., Zsembik,
L. C. P., Thomopoulos, S. I., Zhu, A. H., Strike, L. T., Agartz, I., Alhusaini, S., Almeida,
M. A. A., Alnæs, D., … Enhancing NeuroImaging Genetics through Meta-Analysis
Consortium (ENIGMA)—Genetics working group. (2020). The genetic architecture of the
human cerebral cortex. *Science*, *367*(6484). https://doi.org/10.1126/science.aay6690

Griffanti, L., Zamboni, G., Khan, A., Li, L., Bonifacio, G., Sundaresan, V., Schulz, U. G.,
Kuker, W., Battaglini, M., Rothwell, P. M., & Jenkinson, M. (2016). BIANCA (Brain
Intensity AbNormality Classification Algorithm): A new tool for automated segmentation
of white matter hyperintensities. *NeuroImage*, *141*, 191–205.

Hamer, M., & Batty, G. D. (2019). Association of body mass index and waist-to-hip ratio with
brain structure. *Neurology*, *92*(6), e594–e600.

Iadecola, C., & Gottesman, R. F. (2019). Neurovascular and Cognitive Dysfunction in
Hypertension. *Circulation Research*, *124*(7), 1025–1044.

Jenkinson, M., Beckmann, C. F., Behrens, T. E. J., Woolrich, M. W., & Smith, S. M. (2012).
FSL. *NeuroImage*, *62*(2), 782–790.

Kanekiyo, T., Xu, H., & Bu, G. (2014). ApoE and Aβ in Alzheimer's disease: accidental encounters or partners? *Neuron*, *81*(4), 740–754.

Karlsson, H. K., Tuulari, J. J., Hirvonen, J., Lepomäki, V., Parkkola, R., Hiltunen, J., Hannukainen, J. C., Soinio, M., Pham, T., Salminen, P., Nuutila, P., & Nummenmaa, L. (2013). Obesity is associated with white matter atrophy: a combined diffusion tensor imaging and voxel-based morphometric study. *Obesity* , *21*(12), 2530–2537.

Kinney, J. W., Bemiller, S. M., Murtishaw, A. S., Leisgang, A. M., Salazar, A. M., & Lamb, B. T. (2018). Inflammation as a central mechanism in Alzheimer's disease. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*, *4*, 575–590.

Klein, A., & Tourville, J. (2012). 101 labeled brain images and a consistent human cortical labeling protocol. *Frontiers in Neuroscience*, *6*(DEC). https://doi.org/10.3389/fnins.2012.00171

Littlejohns, T. J., Holliday, J., Gibson, L. M., Garratt, S., Oesingmann, N., Alfaro-Almagro, F., Bell, J. D., Boultwood, C., Collins, R., Conroy, M. C., Crabtree, N., Doherty, N., Frangi, A. F., Harvey, N. C., Leeson, P., Miller, K. L., Neubauer, S., Petersen, S. E., Sellors, J., … Allen, N. E. (2020). The UK Biobank imaging enhancement of 100,000 participants: rationale, data collection, management and future directions. *Nature Communications*, *11*(1), 2624.

Lloret, A., Monllor, P., Esteve, D., Cervera-Ferri, A., & Lloret, M. A. (2019). Obesity as a risk factor for Alzheimer's disease: Implication of leptin and glutamate. *Frontiers in Neuroscience*, *13*(MAY), 508.

Mahley, R. W. (1988). Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. *Science*, *240*(4852), 622–630.

Martens, Y. A., Zhao, N., Liu, C.-C., Kanekiyo, T., Yang, A. J., Goate, A. M., Holtzman, D. M., & Bu, G. (2022). ApoE Cascade Hypothesis in the pathogenesis of Alzheimer's disease and related dementias. *Neuron*, *110*(8), 1304–1317.

Meakin, P. J., Coull, B. M., Tuharska, Z., McCaffery, C., Akoumianakis, I., Antoniades, C., Brown, J., Griffin, K. J., Platt, F., Ozber, C. H., Yuldasheva, N. Y., Makava, N., Skromna,

A., Prescott, A., McNeilly, A. D., Siddiqui, M., Palmer, C. N., Khan, F., & Ashford, M. L. (2020). Elevated circulating amyloid concentrations in obesity and diabetes promote vascular dysfunction. *The Journal of Clinical Investigation*, *130*(8), 4104–4117.

Miller, K. L., Alfaro-Almagro, F., Bangerter, N. K., Thomas, D. L., Yacoub, E., Xu, J., Bartsch, A. J., Jbabdi, S., Sotiropoulos, S. N., Andersson, J. L. R. R., Griffanti, L., Douaud, G., Okell, T. W., Weale, P., Dragonu, I., Garratt, S., Hudson, S., Collins, R., Jenkinson, M., … Smith, S. M. (2016). Multimodal population brain imaging in the UK Biobank prospective epidemiological study. *Nature Neuroscience*, *19*, 1523–1536.

Mole, J. P., Fasano, F., Evans, J., Sims, R., Hamilton, D. A., Kidd, E., & Metzler-Baddeley, C. (2020). Genetic risk of dementia modifies obesity effects on white matter myelin in cognitively healthy adults. *Neurobiology of Aging*, *94*, 298–310.

Mori, S., Wakana, S., Nagae-Poetscher, L., & van Zijl, P. (2005). *MRI atlas of human white matter*. Elsevier B.V.

Moroz, N., Tong, M., Longato, L., Xu, H., & De La Monte, S. M. (2008). Limited Alzheimer-type neurodegeneration in experimental obesity and type 2 diabetes mellitus. *Journal of Alzheimer's Disease: JAD*, *15*(1), 29–44.

Morys, F., Dadar, M., & Dagher, A. (2021). Association Between Midlife Obesity and Its Metabolic Consequences, Cerebrovascular Disease, and Cognitive Decline. *The Journal of Clinical Endocrinology and Metabolism*, *106*(10), e4260–e4274.

Morys, F., Potvin, O., Zeighami, Y., Vogel, J., Lamontagne-Caron, R., Duchesne, S., Dagher, A., & Alzheimer's Disease Neuroimaging Initiative. (2023). Obesity-Associated Neurodegeneration Pattern Mimics Alzheimer's Disease in an Observational Cohort Study. *Journal of Alzheimer's Disease: JAD*, *91*(3), 1059–1071.

Mullins, R. J., Diehl, T. C., Chia, C. W., & Kapogiannis, D. (2017). Insulin Resistance as a Link between Amyloid-Beta and Tau Pathologies in Alzheimer's Disease. *Frontiers in Aging Neuroscience*, *9*, 118.

Mun, K. T., & Hinman, J. D. (2022). Inflammation and the Link to Vascular Brain Health: Timing Is Brain. *Stroke; a Journal of Cerebral Circulation*, *53*(2), 427–436.

Nianogo, R. A., Rosenwohl-Mack, A., Yaffe, K., Carrasco, A., Hoffmann, C. M., & Barnes, D. E. (2022). Risk Factors Associated With Alzheimer Disease and Related Dementias by Sex and Race and Ethnicity in the US. *JAMA Neurology*, *79*(6), 584–591.

O'Dwyer, L., Lamberton, F., Matura, S., Tanner, C., Scheibe, M., Miller, J., Rujescu, D., Prvulovic, D., & Hampel, H. (2012). Reduced hippocampal volume in healthy young ApoE4 carriers: an MRI study. *PloS One*, *7*(11), e48895.

Pastor, P., Moreno, F., Clarimón, J., Ruiz, A., Combarros, O., Calero, M., López de Munain, A., Bullido, M. J., de Pancorbo, M. M., Carro, E., Antonell, A., Coto, E., Ortega-Cubero, S., Hernandez, I., Tárraga, L., Boada, M., Lleó, A., Dols-Icardo, O., Kulisevsky, J., … Dementia Genetic Spanish Consortium (DEGESCO). (2016). MAPT H1 haplotype is associated with late-onset Alzheimer's disease risk in APOE ε4 noncarriers: Results from the dementia genetics Spanish consortium. *Journal of Alzheimer's Disease: JAD*, *49*(2), 343–352.

Patenaude, B., Smith, S. M., Kennedy, D. N., & Jenkinson, M. (2011). A Bayesian model of shape and appearance for subcortical brain segmentation. *NeuroImage*, *56*(3), 907–922.

Pedditizi, E., Peters, R., & Beckett, N. (2016). The risk of overweight/obesity in mid-life and late life for the development of dementia: A systematic review and meta-analysis of longitudinal studies. *Age and Ageing*, *45*(1), 14–21.

Pegueroles, J., Pané, A., Vilaplana, E., Montal, V., Bejanin, A., Videla, L., Carmona-Iragui, M., Barroeta, I., Ibarzabal, A., Casajoana, A., Alcolea, D., Valldeneu, S., Altuna, M., de Hollanda, A., Vidal, J., Ortega, E., Osorio, R., Convit, A., Blesa, R., … Alzheimer's Disease Neuroimaging Initiative. (2020). Obesity impacts brain metabolism and structure independently of amyloid and tau pathology in healthy elderly. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*, *12*(1), e12052.

Pievani, M., Galluzzi, S., Thompson, P. M., Rasser, P. E., Bonetti, M., & Frisoni, G. B. (2011). APOE4 is associated with greater atrophy of the hippocampal formation in Alzheimer's disease. *NeuroImage*, *55*(3), 909–919.

Planche, V., Manjon, J. V., Mansencal, B., Lanuza, E., Tourdias, T., Catheline, G., & Coupé, P. (2022). Structural progression of Alzheimer's disease over decades: the MRI staging scheme. *Brain Communications*, *4*(3), fcac109.

Platt, T. L., Beckett, T. L., Kohler, K., Niedowicz, D. M., & Murphy, M. P. (2016). Obesity, Diabetes, and Leptin Resistance Promote Tau Pathology in a Mouse Model of Disease. *Neuroscience*, *315*, 162.

Reitz, C. (2013). Dyslipidemia and the risk of alzheimer's disease. In *Current Atherosclerosis Reports* (Vol. 15, Issue 3, p. 307). Current Medicine Group LLC 1. https://doi.org/10.1007/s11883-012-0307-3

Sánchez-Juan, P., Moreno, S., de Rojas, I., Hernández, I., Valero, S., Alegret, M., Montrreal, L., García González, P., Lage, C., López-García, S., Rodríiguez-Rodríguez, E., Orellana, A., Tárraga, L., Boada, M., & Ruiz, A. (2019). The MAPT H1 haplotype is a risk factor for Alzheimer's disease in APOE ε4 non-carriers. *Frontiers in Aging Neuroscience*, *11*, 327.

Setó-Salvia, N., Clarimón, J., Pagonabarraga, J., Pascual-Sedano, B., Campolongo, A., Combarros, O., Mateo, J. I., Regaña, D., Martínez-Corral, M., Marquié, M., Alcolea, D., Suárez-Calvet, M., Molina-Porcel, L., Dols, O., Gómez-Isla, T., Blesa, R., Lleó, A., & Kulisevsky, J. (2011). Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes: Disentangling the role of MAPT haplotypes. *Archives of Neurology*, *68*(3), 359–364.

Silva, M. V. F., Loures, C. de M. G., Alves, L. C. V., de Souza, L. C., Borges, K. B. G., & Carvalho, M. das G. (2019). Alzheimer's disease: risk factors and potentially protective measures. *Journal of Biomedical Science*, *26*(1), 33.

So, S. W., Fleming, K. M., Nixon, J. P., & Butterick, T. A. (2023). Early Life Obesity Increases Neuroinflammation, Amyloid Beta Deposition, and Cognitive Decline in a Mouse Model of Alzheimer's Disease. *Nutrients*, *15*(11). https://doi.org/10.3390/nu15112494

Spillantini, M. G., & Goedert, M. (2013). Tau pathology and neurodegeneration. *Lancet Neurology*, *12*(6), 609–622.

Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P.,
Green, J., Landray, M., Liu, B., Matthews, P., Ong, G., Pell, J., Silman, A., Young, A.,
Sprosen, T., Peakman, T., & Collins, R. (2015). UK Biobank: An Open Access Resource
for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old
Age. *PLoS Medicine*, *12*(3), e1001779.

Sun, Y.-Y., Wang, Z., & Huang, H.-C. (2023). Roles of ApoE4 on the Pathogenesis in
Alzheimer's Disease and the Potential Therapeutic Approaches. *Cellular and Molecular
Neurobiology*, *43*(7), 3115–3136.

van den Kerkhof, M., van der Thiel, M. M., Postma, A. A., van Oostenbrugge, R. J., Kroon,
A. A., Jansen, J. F. A., & Backes, W. H. (2023). Hypertension Correlates With Stronger
Blood Flow Pulsatility in Small Perforating Cerebral Arteries Assessed With 7 Tesla
Magnetic Resonance Imaging. *Hypertension*, *80*(4), 802–810.

Wakana, S., Caprihan, A., Panzenboeck, M. M., Fallon, J. H., Perry, M., Gollub, R. L., Hua,
K., Zhang, J., Jiang, H., Dubey, P., Blitz, A., van Zijl, P., & Mori, S. (2007).
Reproducibility of quantitative tractography methods applied to cerebral white matter.
NeuroImage, *36*(3), 630–644.

Walker, J. M., Dixit, S., Saulsberry, A. C., May, J. M., & Harrison, F. E. (2017). Reversal of
high fat diet-induced obesity improves glucose tolerance, inflammatory response,
β-amyloid accumulation and cognitive decline in the APP/PSEN1 mouse model of
Alzheimer's disease. *Neurobiology of Disease*, *100*, 87–98.

Wang, H., Makowski, C., Zhang, Y., Qi, A., Kaufmann, T., Smeland, O. B., Fiecas, M., Yang,
J., Visscher, P. M., & Chen, C.-H. (2023). Chromosomal inversion polymorphisms shape
human brain morphology. *Cell Reports*, *42*(8), 112896.

Yu, J.-T., Xu, W., Tan, C.-C., Andrieu, S., Suckling, J., Evangelou, E., Pan, A., Zhang, C., Jia,
J., Feng, L., Kua, E.-H., Wang, Y.-J., Wang, H.-F., Tan, M.-S., Li, J.-Q., Hou, X.-H., Wan,
Y., Tan, L., Mok, V., … Vellas, B. (2020). Evidence-based prevention of Alzheimer's
disease: systematic review and meta-analysis of 243 observational prospective studies
and 153 randomised controlled trials. *Journal of Neurology, Neurosurgery, and*

Psychiatry, *91*(11), 1201–1209.

Zhang, R., Beyer, F., Lampe, L., Luck, T., Riedel-Heller, S. G., Loeffler, M., Schroeter, M. L.,

Stumvoll, M., Villringer, A., & Witte, A. V. (2018). White matter microstructural variability

mediates the relation between obesity and cognition in healthy adults. *NeuroImage*,

172, 239–249.

Zody, M. C., Jiang, Z., Fung, H.-C., Antonacci, F., Hillier, L. W., Cardone, M. F., Graves, T. A.,

Kidd, J. M., Cheng, Z., Abouelleil, A., Chen, L., Wallis, J., Glasscock, J., Wilson, R. K.,

Reily, A. D., Duckworth, J., Ventura, M., Hardy, J., Warren, W. C., & Eichler, E. E.

(2008). Evolutionary toggling of the MAPT 17q21.31 inversion region. *Nature Genetics*,

40(9), 1076–1083.

10. Supplementary Figures

Figure S1 Eigenvalues of principal component analysis conducted to obtain an overall metabolic risk score

Figure S2 Associations between white matter hyperintensities (WMH) load and brain structure. **a** Associations between WMH and cortical surface area/thickness; **b** Associations between WMH and subcortical volumes; **c** Moderation of *APOE* ε4 carrier status on the relationship between WMH volume and hippocampal volume; **d** Moderation of *MAPT* haplotype on the relationship between WMH volume and pallidum volume.

Figure S3 Associations between metabolic risk score (rotated component 1; RC1) and brain structure. **a** Associations between RC1 and cortical surface area/thickness; **b** Associations between RC1 and subcortical volumes; **c** Brain regions whose relationship is between RC1 and surface area is moderated by *APOE* ε4 carrier status; **d** Moderation of *APOE* ε4 carrier status on the relationship between RC1 and cortical surface area (data residualised for all covariates included in the model are plotted).

Figure S4 Associations between white metabolic risk score (rotated component 1; RC1) and white matter microstructure. **a** Associations between RC1 and fractional anisotropy; **b** Associations between RC1 and mean diffusivity.

Figure S5 Associations between white matter hyperintensities (WMH) volume and prospective memory - moderation by APOE ε4 carrier status.

Figure S6 Association between overall metabolic risk score (rotated component 1, RC1) and visuospatial memory - moderation by H1 haplotype status.